Associations between soluble PD-L1/PD-1 and circulating immune cells for prostate cancer progression

被引：0
|
作者：
Survila, Zilvinas [1 ]
Pasukoniene, Vita [2 ]
Zvirble, Margarita [2 ,3 ]
机构：
[1] Vilnius Univ, Life Sci Ctr, Inst Biosci, Vilnius, Lithuania
[2] Natl Canc Inst, Vilnius, Lithuania
[3] Vilnius Univ, Life Sci Ctr, Vilnius, Lithuania
来源：
EUROPEAN JOURNAL OF IMMUNOLOGY | 2024年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
2251 - P3.
引用
收藏
页码：1630 / 1630
页数：1
相关论文
共 50 条
  • [41] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
    Duruisseaux, Michael
    Rouquette, Isabelle
    Adam, Julien
    Cortot, Alexis
    Cazes, Aurelie
    Gibault, Laure
    Damotte, Diane
    Lantuejoul, Sylvie
    ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
  • [42] POTENTIAL AS BIOMARKERS OF SOLUBLE PD-1 AND PD-L1 IN HEPATOCELLULAR CARCINOMA
    Kanzaki, Hiroaki
    Chiba, Tetsuhiro
    Kato, Naoya
    HEPATOLOGY, 2019, 70 : 1218A - 1218A
  • [43] PD-1/PD-L1 inhibitors
    Sunshine, Joel
    Taube, Janis M.
    CURRENT OPINION IN PHARMACOLOGY, 2015, 23 : 32 - 38
  • [44] Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression
    Saito, Hiroaki
    Kono, Yusuke
    Murakami, Yuki
    Shishido, Yuji
    Kuroda, Hirohiko
    Matsunaga, Tomoyuki
    Fukumoto, Yoji
    Osaki, Tomohiro
    Ashida, Keigo
    Fujiwara, Yoshiyuki
    ANTICANCER RESEARCH, 2018, 38 (01) : 107 - 112
  • [45] PD-1/PD-L1 in disease
    Kuol, Nyanbol
    Stojanovska, Lily
    Nurgali, Kulmira
    Apostolopoulos, Vasso
    IMMUNOTHERAPY, 2018, 10 (02) : 149 - 161
  • [46] PD-1/PD-L1 expression and molecular associations in HPB malignancies
    Mody, Kabir
    Feldman, Rebecca
    Reddy, Sandeep K.
    Reynolds, Gina A.
    McMillan, Jessica M.
    Johnson, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [47] Interplay between inflammasomes and PD-1/PD-L1 and their implications in cancer immunotherapy
    Jiao, Zhongyu
    Zhang, Jun
    CARCINOGENESIS, 2023, 44 (12) : 795 - 808
  • [48] Prognostic significance of soluble PD-L1 in prostate cancer
    Zvirble, Margarita
    Survila, Zilvinas
    Bosas, Paulius
    Dobrovolskiene, Neringa
    Mlynska, Agata
    Zaleskis, Gintaras
    Jursenaite, Jurgita
    Characiejus, Dainius
    Pasukoniene, Vita
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [49] Is it possible to rechallenge with PD-1/PD-L1 inhibitors after progression?
    Saleh, Khalil
    Khalifeh-Saleh, Nadine
    Kourie, Hampig Raphael
    IMMUNOTHERAPY, 2018, 10 (05) : 345 - 347
  • [50] PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
    Parvez, Adil
    Choudhary, Furqan
    Mudgal, Priyal
    Khan, Rahila
    Qureshi, Kamal A.
    Farooqi, Humaira
    Aspatwar, Ashok
    FRONTIERS IN IMMUNOLOGY, 2023, 14
12345